Shuttle Pharmaceuticals Stock Total Debt
| SHPH Stock | USD 0.79 0.04 5.33% |
Shuttle Pharmaceuticals fundamentals help investors to digest information that contributes to Shuttle Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Shuttle Stock. The fundamental analysis module provides a way to measure Shuttle Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shuttle Pharmaceuticals stock.
The current Total Debt To Capitalization is estimated to decrease to 0.23. Shuttle | Total Debt |
Shuttle Pharmaceuticals Company Total Debt Analysis
Shuttle Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Shuttle Pharmaceuticals Total Debt | 1.09 M |
Most of Shuttle Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shuttle Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Shuttle Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Shuttle Pharmaceuticals is extremely important. It helps to project a fair market value of Shuttle Stock properly, considering its historical fundamentals such as Total Debt. Since Shuttle Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Shuttle Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Shuttle Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Shuttle Total Debt Historical Pattern
Today, most investors in Shuttle Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Shuttle Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Shuttle Pharmaceuticals total debt as a starting point in their analysis.
Shuttle Pharmaceuticals Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Shuttle Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Shuttle Pharmaceuticals has a Total Debt of 1.09 M. This is 99.96% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is 99.98% higher than that of the company.
Shuttle Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shuttle Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shuttle Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Shuttle Pharmaceuticals by comparing valuation metrics of similar companies.Shuttle Pharmaceuticals is currently under evaluation in total debt category among its peers.
Shuttle Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Shuttle Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Shuttle Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Shuttle Pharmaceuticals' value.| Shares | Hrt Financial Llc | 2024-09-30 | 25.9 K | Tower Research Capital Llc | 2024-09-30 | 3.9 K | Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 63.0 | Bank Of America Corp | 2024-09-30 | 9.0 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 |
Shuttle Fundamentals
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.62 | ||||
| Current Valuation | 3.61 M | ||||
| Shares Outstanding | 4.08 M | ||||
| Shares Owned By Insiders | 27.80 % | ||||
| Shares Owned By Institutions | 1.81 % | ||||
| Number Of Shares Shorted | 8.97 K | ||||
| Price To Book | 4.16 X | ||||
| EBITDA | (3.99 M) | ||||
| Net Income | (6.59 M) | ||||
| Cash And Equivalents | 50.44 K | ||||
| Total Debt | 1.09 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 0.03 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (5.58 M) | ||||
| Short Ratio | 0.25 X | ||||
| Earnings Per Share | (4.25) X | ||||
| Beta | 0.74 | ||||
| Market Capitalization | 3.2 M | ||||
| Total Asset | 5.95 M | ||||
| Retained Earnings | (25.43 M) | ||||
| Working Capital | 4.55 M | ||||
| Net Asset | 5.95 M |
About Shuttle Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shuttle Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shuttle Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shuttle Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Shuttle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Shuttle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Shuttle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Shuttle Pharmaceuticals Stock:Check out Shuttle Pharmaceuticals Piotroski F Score and Shuttle Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.